Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ming‐Tao Wen
Observed names:
Ming-Tao Wen,
Ming-tao Wen,
Wen, Ming-Tao
Institution:
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Observed institutions:
Shandong University of Traditional Chinese Medicine,
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
ORCID:
0000-0002-1654-2264
Observed ORCID:
0000-0002-1654-2264
OpenAlex ID:
A5005913273
Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
2024
·
Ming-Tao Wen
, Jia-Cheng Li
, et al.
·
Frontiers in Pharmacology
·
36
Identification of potential autophagy-related genes in steroid-induced osteonecrosis of the femoral head via bioinformatics analysis and experimental verification
2022
·
Xue-Zhen Liang
, Di Luo
, et al.
·
Journal of Orthopaedic Surgery and Research
·
26
PDF
Pyroptosis -related potential diagnostic biomarkers in steroid-induced osteonecrosis of the femoral head
2023
·
Jin-Lian Chai
, Bo-Wen Lu
, et al.
·
BMC Musculoskeletal Disorders
·
22
PDF
Plasma lipids, alcohol intake frequency and risk of Osteoarthritis: a Mendelian randomization study
2023
·
Ming-Tao Wen
, Xue-Zhen Liang
, et al.
·
BMC Public Health
·
20
PDF
IRF8 and its related molecules as potential diagnostic biomarkers or therapeutic candidates and immune cell infiltration characteristics in steroid-induced osteonecrosis of the femoral head
2023
·
Xue-Zhen Liang
, Xiao-Chen Liu
, et al.
·
Journal of Orthopaedic Surgery and Research
·
19
PDF
The Effect of the Hip Flexion Angle in Osteonecrosis of the Femoral Head Based on China‐Japan Friendship Hospital Classification ‐ A Finite Element Study
2023
·
Ming‐Tao Wen
, Xue‐Zhen Liang
, et al.
·
Orthopaedic Surgery
·
12
PDF
Safety comparisons among different subcutaneous anticoagulants for venous thromboembolism using FDA adverse event reporting system
2025
·
Bo-wen Lu
, Jia-cheng Li
, et al.
·
Scientific Reports
·
6
PDF
Comparing musculoskeletal and connective tissue disorder risks of teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS)
2024
·
Ming-Tao Wen
, Di Luo
, et al.
·
Expert Opinion on Drug Safety
·
6
Show more works
View as search
Works count:
9
Citation count:
147
H-index:
6
I10-index:
6
Year
Topic
Type